HC Wainwright started coverage on shares of Cardiol Therapeutics (NASDAQ:CRDL - Free Report) in a research note issued to investors on Monday morning, Marketbeat reports. The firm issued a buy rating and a $9.00 price objective on the stock.
Cardiol Therapeutics Price Performance
NASDAQ CRDL traded up $0.07 on Monday, hitting $1.31. The stock had a trading volume of 292,900 shares, compared to its average volume of 357,676. Cardiol Therapeutics has a 52-week low of $0.77 and a 52-week high of $3.12. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49. The company has a market capitalization of $108.22 million, a price-to-earnings ratio of -3.36 and a beta of 0.98. The firm has a 50-day moving average of $1.05 and a 200-day moving average of $1.22.
Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. Equities analysts expect that Cardiol Therapeutics will post -0.33 EPS for the current year.
Institutional Trading of Cardiol Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in CRDL. Tejara Capital Ltd raised its position in shares of Cardiol Therapeutics by 75.9% during the 4th quarter. Tejara Capital Ltd now owns 3,115,437 shares of the company's stock valued at $3,988,000 after buying an additional 1,344,167 shares in the last quarter. PVG Asset Management Corp purchased a new stake in shares of Cardiol Therapeutics during the 4th quarter valued at $624,000. Envestnet Asset Management Inc. purchased a new stake in shares of Cardiol Therapeutics during the 4th quarter valued at $398,000. Atria Investments Inc purchased a new stake in shares of Cardiol Therapeutics during the 4th quarter valued at $174,000. Finally, Virtu Financial LLC purchased a new stake in shares of Cardiol Therapeutics during the 4th quarter valued at $61,000. Hedge funds and other institutional investors own 12.49% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Articles
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
